Shares of Recro Pharma Inc (NASDAQ:REPH) have been assigned a consensus rating of “Buy” from the seven brokerages that are covering the company. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $19.67.
A number of research analysts have recently commented on the stock. Piper Jaffray Companies assumed coverage on shares of Recro Pharma in a report on Monday, December 19th. They issued an “overweight” rating and a $12.00 target price for the company. Zacks Investment Research cut shares of Recro Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, March 21st. HC Wainwright reissued a “buy” rating and issued a $19.00 target price on shares of Recro Pharma in a report on Tuesday, November 29th. Finally, Roth Capital set a $24.00 target price on shares of Recro Pharma and gave the stock a “buy” rating in a report on Monday, November 28th.
Recro Pharma (NASDAQ:REPH) opened at 7.96 on Wednesday. The company’s market cap is $151.64 million. The company’s 50-day moving average is $7.84 and its 200 day moving average is $7.91. Recro Pharma has a 1-year low of $5.75 and a 1-year high of $12.50.
In other news, major shareholder Scp Vitalife Partners Ii Lp sold 44,977 shares of the company’s stock in a transaction that occurred on Thursday, March 16th. The stock was sold at an average price of $8.00, for a total value of $359,816.00. Following the completion of the transaction, the insider now owns 2,276,571 shares of the company’s stock, valued at $18,212,568. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Scp Vitalife Partners (Israel) sold 4,030 shares of the company’s stock in a transaction that occurred on Thursday, February 16th. The shares were sold at an average price of $7.89, for a total value of $31,796.70. Following the completion of the transaction, the insider now directly owns 772,714 shares of the company’s stock, valued at approximately $6,096,713.46. The disclosure for this sale can be found here. Insiders sold 58,990 shares of company stock valued at $467,384 in the last three months. Company insiders own 39.30% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in REPH. Dimensional Fund Advisors LP purchased a new position in Recro Pharma during the fourth quarter valued at about $118,000. Acadian Asset Management LLC purchased a new position in Recro Pharma during the third quarter valued at about $140,000. Wells Fargo & Company MN increased its position in Recro Pharma by 56.0% in the third quarter. Wells Fargo & Company MN now owns 31,200 shares of the specialty pharmaceutical company’s stock valued at $276,000 after buying an additional 11,200 shares in the last quarter. Numeric Investors LLC purchased a new position in Recro Pharma during the fourth quarter valued at about $556,000. Finally, Granite Point Capital Management L.P. purchased a new position in Recro Pharma during the third quarter valued at about $636,000. 53.23% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by Mideast Time and is the sole property of of Mideast Time. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.mideasttime.com/recro-pharma-inc-reph-receives-average-recommendation-of-buy-from-analysts/1589018.html.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.